Tatiana V. Gorbunova

Tatiana V. Gorbunova

Auto-generated profile, based on publicly available information

Tatiana V. Gorbunova

N.N. Blokhin National Medical Research Center of Oncology of Ministry of Health of the Russian Federation

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2024 in Russian Journal of Pediatric Hematology and Oncology
Verified
Journal Article
Open access
PDF file
SKS. A. Kulyova
S. A. Kulyova
SVS. R. Varfolomeeva
S. R. Varfolomeeva
KKKirill Kirgizov
Kirill Kirgizov
EPElizaveta Prosekina
Elizaveta Prosekina
ORO. M. Romantsova
O. M. Romantsova
TGT. V. Gorbunova
T. V. Gorbunova
Introduction. Tumor-associated gangliosides are overexpressed on a large number of tumors. The ratio of the amount of gangliosides varies from one type of tumor to another. Tissue restriction of GD2 expression in normal cells and its presence in a wide range of human tumor diseases has increased the relevance of GD2 as a target for immunooncology drugs.The aim of the study was to improve the efficacy of the treatment of children and adolescents with refractory and recurrent solid malignancies (soft tissue, undifferentiated and bone sarcomas) by incorporating targeted immunotherapeutic options (passive immunotherapy with antiGD2 monoclonal antibodies (MA)) into comprehensive therapy programs.The primary objective of the study was to analyze the efficacy of tandem use of antiGD2 MA and 2+ line chemotherapy on survival. Secondary targets were overall response rate (complete remission (CR) + partial remission (PR)), tumor control rate (CR + PR + stabilization), duration of response, and immune-associated adverse events.Materials and methods. The clinical study protocol was initiated at the Petrov National Medical Research Center of Oncology of the Ministry of Health of Russia and approved by the local ethics committee No. 8 of 21.05.2021. On the basis of a signed memorandum of cooperation, the Research Institute of Pediatric Oncology and Hematology named after Academician of the Russian Academy of Medical Sciences L.A. Durnov at N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia.The study is prospective. It is planned to evaluate the efficacy and safety of using antiGD2 MA and 2+ line chemotherapy at the investigator's choice in patients under 18 years of age with bone, soft tissue and undifferentiated sarcomas with positive GD2 expression and disease progression/recurrence on/after the 1st line of polychemotherapy.This study screened 40 patients to randomize 10 patients. In the future, an additional set of patients is planned.Conclusion. Based on the results obtained, the efficacy and safety of using a combination of antiGD2 immunotherapy and 2+ line chemotherapy in patients under 18 years of age with refractory and recurrent forms of bone and soft-tissue GD2-positive sarcomas will be concluded.

19 January 2025 in Russian Journal of Pediatric Hematology and Oncology
Verified
Journal Article
Open access
PDF file
SKS. A. Kulyova
S. A. Kulyova
SVS. R. Varfolomeeva
S. R. Varfolomeeva
KKKirill Kirgizov
Kirill Kirgizov
EPElizaveta Prosekina
Elizaveta Prosekina
ORO. M. Romantsova
O. M. Romantsova
NMN. V. Matinyan
N. V. Matinyan
Background. In the literature, information on the overexpression of disialoganglioside GD2 on the cells of malignant neoplasms is not uncommon. In this regard, this marker should be considered as a tumor-associated antigen, which may be a target on the cell surface in patients with poor prognosis.The aim of the study – improve the efficacy of the treatment of children and adolescents with refractory and recurrent solid malignancies (soft tissue, undifferentiated (unSA) and bone sarcomas) by incorporating targeted immunotherapeutic options (immunotherapy with antiGD2 monoclonal antibodies (MA)) into comprehensive therapy programs.Materials and methods. Ten patients with GD2-positive relapsed/refractory soft tissue sarcomas (STS, n = 4), osteosarcomas (OS, n = 2), Ewingʼs sarcomas (ES, n = 4) and unSA (n = 1) were included in the study. The gender ratio was 2.3:1 (boys:girls). The mean age at the time of inclusion in the study was 12 ± 2 years. The most of all patients (80 %) had a status of “primary resistant disease”. GD2 quantitative expression level was 29 ± 11 % (0.9 to 85 %). Patients were represented by deeply pretreated patients who received 8 to 25 cycles of 2+ line chemotherapy (mean 13). A total of 7 patients completed the full reinduction treatment (6 cycles of chemoimmunotherapy). All patients received anti-GD2 MA 100 mg/m2 as an intravenous 5-day infusion every 4 weeks, and treatment was continued until disease progression or 6 cycles. Fifty-two cycles of immunotherapy were performed.Results. Pain syndrome was the most frequently diagnosed (after 16 cycles, or in 30.7 % of cases); 5 (9.6 %) cycles each were accompanied by diarrhea, cytokine release syndrome, and increased capillary permeability syndrome. The immediate results varied according to the histological subtype of the tumor. The overall objective response rate was 43 % (3/7): 2 patients achieved complete remission (CR) and one achieved partial remission (PR). The disease control rate (CR + PR + stable) was 86 % (6/7). The clinical response rate 6 months after completion of chemoimmunotherapy ranged from 0 % (2/2) in ES to 50 % (1/2) in OS. In 43 % (3/7) of evaluable patients, disease progression was diagnosed after a mean of 5 months. At follow-up after 12 and 24 months, CR persisted in all patients with STS (100 %). Progression-free survival (PFS) in patients with STS at 6, 12 and 24 months was 100 % (PFS6, PFS12, PFS24, respectively). PFS6 in OS and ES patients was 100 % and 50 %, respectively, gradually decreasing to 0 %. The study revealed a very strong positive straight-line positive functional correlation between quantitative GD2 expression and progression-free survival (r = 0.971, p = 0.00006).Conclusion. Passive immunotherapy with monoclonal antibodies is a safe treatment method without severe immune-related adverse reactions. Patient follow-up and evaluation of the efficacy and safety of the drug after the end of the therapy plan continues until today, which allows a more detailed and objective evaluation of the results of immunotherapy according to the purpose of the study.

22 January 2020 in Russian Journal of Pediatric Hematology and Oncology
Verified
Journal Article
Open access
PDF file
TUT. L. Ushakova
T. L. Ushakova
AVA. S. Volkova
A. S. Volkova
TGT. V. Gorbunova
T. V. Gorbunova
OGO. V. Gorovtsova
O. V. Gorovtsova
IDI. S. Dolgopolov
I. S. Dolgopolov
VPV. G. Polyakov
V. G. Polyakov
Ретинобластома с экстраокулярным ростом по зрительному нерву: клинический случай

24 July 2019 in Oncopediatrics
Verified
Journal Article
Open access
PDF file
TGTatiana V. Gorbunova
Tatiana V. Gorbunova
ARAnastasia D. Rodina
Anastasia D. Rodina
RSRuslan V. Shishkov
Ruslan V. Shishkov
NINatalia V. Ivanova
Natalia V. Ivanova
IGIgor V. Glekov
Igor V. Glekov
VPVladimir G. Polyakov
Vladimir G. Polyakov
The incidence of esthesioneuroblastoma in children under 15 years of age is 0.1 per 100.000 children. Distinctive histological features of this tumor are diffuse accumulation of neuron-specific enolase, synaptophysin, chromogranin, and variable expression of cytokeratins. Diagnosis of the tumor includes endoscopic examination of the nasal cavity and nasopharynx, magnetic resonance imaging (MRI) and computed tomography (CT) of the skull base, paranasal sinuses with intravenous contrast. PET-CT is advisable to use for the detection of regional and distant metastases, as well as for suspected relapse. In patients of adult age, a negative effect on the outcome of the disease was detected, the detection of metastases in the lymph nodes of the neck, the presence of tumor cells at the edges of tumor resection and a high degree of malignancy of the tumor according to the Hyams system. Therapeutic approaches depend on the stage of esthesioneuroblastoma by Kadish. In the A-stage, surgical treatment is advisable. In the presence of tumor cells at the edges of the resection or residual tumor, radiation therapy is performed. In case of B-stage, surgical treatment is combined with the mandatory irradiation of the primary tumor area. In patients with the C-stage, neoadjuvant chemotherapy or radiation is performed, followed by a surgical treatment, adjuvant chemotherapy and/or radiation therapy. Patients with D-stage chemoradiation therapy is indicated. There is no consensus on an effective drug regimen. Overall 5-year survival varies significantly depending on the design of the study — 55% to 98%. Further study of the features of the clinical picture, morphological and molecular features and the course of the disease will help to improve our understanding of the nature of the tumor.

1 January 2017 in Oncopediatrics
Verified
Journal Article
Open access
PDF file
OMO. A. Merkulov
O. A. Merkulov
TGT. V. Gorbunova
T. V. Gorbunova
VPV. G. Polyakov
V. G. Polyakov
Обоснование. Эстезионейробластома (ЭНБ) — редкая злокачественная опухоль у детей. Целесообразность и эффективность трансназального эндоскопического удаления ЭНБ у детей изучены недостаточно. Цель исследования: изучить возможность проведения трансназальных эндоскопических удалений опухоли в комплексном лечении детей с ЭНБ. Методы. В исследование включено 11 пациентов с диагнозом ЭНБ, которым проводилось лечение с 2003 по 2016 г. Средний возраст пациентов на момент установки диагноза — 9 лет. Преобладали пациенты с IV стадией заболевания — 8 (72,7%). Первичная опухоль распространялась в орбиту у 5 (45,5%) пациентов, в клетки решетчатого лабиринта — у 9 (81,8%), носоглотку — у 2 (18,2%), крылонебную ямку — у 8 (72,7%). Интракраниальное распространение отмечено в 4 (36,4%) случаях. Лекарственное лечение и лучевую терапию получили 8 (72,7%) пациентов. Полихимиотерапия включала от 6 до 10 курсов химиотерапии с использованием препаратов винкристин, циклофосфан, доксорубицин, карбоплатин. Лучевая терапия выполнена 8 (72,7%), трансназальное эндоскопическое удаление опухоли — 6 (54,5%) пациентам, одному из них удаление опухоли трансназальным доступом осуществлялось дважды. Повторная операция была проведена по поводу рецидива заболевания. У двух пациентов было выполнено только оперативное лечение в монорежиме. Результаты. За период наблюдения от 3 мес до 13 лет живы 6 (54,5%) пациентов. Один пациент выбыл из исследования сразу после установления диагноза. Умерли от прогрессии опухоли 4 (36,4%). Заключение. Показана эффективность комплексного лечения детей с распространенными стадиями ЭНБ. Перспективность проведения трансназальных эндоскопических удалений опухоли в комплексном лечении детей с ЭНБ требует дальнейшего изучения и определения четких критериев включения в схемы и протоколы терапии детей с ЭНБ.

1 January 2017 in Oncopediatrics
Verified
Journal Article
Open access
PDF file
OMO. A. Merkulov
O. A. Merkulov
TGT. V. Gorbunova
T. V. Gorbunova
DBD. A. Buletov
D. A. Buletov
VPV. G. Polyakov
V. G. Polyakov
Эндоскопический эндоназальный подход к удалению опухолей полости носа и околоносовых пазух с распространением на основание черепа у детей